Add BrightSurf on Google Email

Preventive tuberculosis treatment wanes after one year in high-burden countries, but lasts for at least 8 to 13 years in low- and medium-burden countries

Researchers found strong initial protection from TB preventive treatment (TPT) in 24 countries, but long-term protection varied depending on TB disease burden. In high-burden settings, protection waned after just one year, while in low- and medium-burden settings, it lasted at least 8 and 13 years, respectively.

SourceBoston University School of Public Health·JournalThe Lancet Respiratory Medicine·TypeMeta-analysis·DateSep 22, 2026

Anti-immigrant ‘public charge’ policy may have contributed to rise in HIV among Hispanic ropulations

A new study found a 16.8-percent increase in HIV cases among Hispanic populations in antisanctuary counties compared to baseline counties. The researchers attributed this increase to the 2018 announcement of changes to the public charge rule, which penalized immigrants for using public benefit programs.

SourceBoston University School of Public Health·JournalMilbank Quarterly·TypeObservational study·DateAug 25, 2026

Study: Triple-dose regimen may permanently clear HIV in infected newborns

Researchers at Oregon Health & Science University have made a groundbreaking discovery in animal models that a one-time treatment regimen can permanently clear HIV from newborns. The study's findings have the potential to advance quickly to human clinical trials, offering new hope for millions of people worldwide who require lifelong t...

SourceOregon Health & Science University·JournalNature Microbiology·TypeExperimental study·DateAug 10, 2026

Research spotlight: Medicare spending on clinical care for people aging with HIV projected to rise steeply over next decade

As more Americans with HIV age into Medicare eligibility, costs are expected to increase substantially. The study projects nearly 200,000 beneficiaries by 2035 and $27.3 billion in annual spending. Policy changes like the Inflation Reduction Act could save billions, while generic HIV medications may further reduce costs.

SourceBrigham and Women's Hospital·JournalJAMA Network Open·TypeData/statistical analysis·DateAug 6, 2026

International study shows once-weekly HIV pill performs as well as daily treatment

An international clinical trial has shown that a once-weekly oral treatment for HIV is non-inferior to one of today's leading daily therapies. The Phase 3 ISLEND-1 trial evaluated a tablet combining islatravir and lenacapavir in adults with well-controlled HIV, demonstrating over 93% viral suppression in both groups.

SourceQueen Mary University of London·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJul 29, 2026

Study spotlights human toll of abrupt U.S. foreign aid cuts

The study found that the funding freeze disrupted sexual and reproductive health and rights, HIV service interruptions, mental health crises, and growing inequities. Researchers propose diversified global health financing, stronger domestic preparedness, and rights-based approaches to mitigate future policy shocks.

SourceColumbia University's Mailman School of Public Health·JournalBMJ Public Health·TypeObservational study·DateJul 22, 2026

Women with HIV are more likely to die from trauma than the virus

A new study by UC San Francisco found that women with HIV are more likely to die from preventable trauma-related conditions like substance use and mental illness. The researchers say these causes are largely missing from official death records, highlighting the need for broader goals in HIV care beyond just controlling the virus.

SourceUniversity of California - San Francisco·JournalJournal of Acquired Immune Deficiency Syndromes & Human Retrovirology·DateJun 12, 2026

Expanded tuberculosis screening does not speed up treatment initiation or improve survival in hospitalized patients with HIV

A clinical trial found that adding molecular tests on urine and stool samples did not speed up treatment initiation or reduce mortality in hospitalized patients with HIV. The study showed no significant difference in treatment initiation within 72 hours between the expanded screening group and the standard group.

SourceBarcelona Institute for Global Health (ISGlobal)·JournalThe Lancet Infectious Diseases·TypeRandomized controlled/clinical trial·DateMay 8, 2026

Waiting to enter primary school may improve educational outcomes in low-income countries, with health benefits into adulthood and the next generation

A new study found that children who start primary school at older ages completed more years of schooling, had greater wealth in adulthood, and fewer teen pregnancies. This delay allowed them to develop greater literacy and was associated with better health outcomes, including lower rates of HIV infection and child death.

SourceBoston University School of Public Health·JournalAmerican Economic Journal Applied Economics·TypeObservational study·DateApr 14, 2026

Machine-learning immune-system analysis study may hold clues to personalized medicine

A York University-led study used machine-learning models to analyze 64 immune biomarkers in people with and without HIV who received COVID-19 vaccines. The researchers found clear vaccine-initiated immune response biomarkers between the two groups, but also identified outliers that provide insights into the complex nature of the immune...

SourceYork University·JournalPatterns·TypeComputational simulation/modeling·DateMar 4, 2026

New tool reveals the secrets of HIV-infected cells

A new tool, HIV-seq, has been developed to profile rare HIV-infected cells from people with HIV. The tool has recovered and analyzed more HIV-infected cells and higher numbers of HIV RNA within those infected cells. The study has identified key differences in people's HIV-infected cells before versus after starting antiretroviral therapy.

SourceGladstone Institutes·JournalNature Communications·DateMar 3, 2026

The Lancet: Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens

A new daily oral tablet combining bictegravir and lenacapavir (BIC/LEN) was found to be highly effective in maintaining HIV suppression, with nearly 96% of participants who switched to this simplified regimen maintaining viral suppression. The treatment showed similar results compared to complex, multi-pill treatments.

SourceThe Lancet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateFeb 25, 2026

Exposing a hidden anchor for HIV replication

Scientists at the University of Delaware discovered a previously unknown structural role for the HIV integrase protein, which forms gluey filaments that anchor the RNA genome to the capsid. This discovery provides a promising new target for drug development and could lead to the development of next-generation inhibitors.

SourceUniversity of Delaware·JournalNature·DateFeb 18, 2026

New antibody–drug conjugate strategy to block HIV infection

Researchers developed antibody–drug conjugates that combine CD4 mimic and neutralizing antibodies to target HIV entry, showing seven times better efficacy than existing approaches. The strategy aims to block HIV before it enters the host cell, offering a more targeted therapeutic profile and potentially reducing adverse effects.

SourceInstitute of Science Tokyo·JournalJournal of Medicinal Chemistry·TypeExperimental study·DateFeb 17, 2026

Research spotlight: Preventive HIV drugs under prescribed to young women at increased risk

Research reveals disparities in access to PrEP among young cisgender females and males, highlighting the need for targeted interventions to improve HIV prevention. The study analyzed data from over 7,000 visits to a Boston-based clinic, finding that only 17% of visits received PrEP for under-age females.

SourceBrigham and Women's Hospital·JournalSexually Transmitted Diseases·TypeData/statistical analysis·DateJan 19, 2026

Studies show that less frequent, all-injectable treatment for HIV is safe and preferred by adolescents

A multinational clinical trial found that the long-term HIV treatment regimen is safe and favored by adolescents who received injectable intramuscular antiviral medications cabotegravir and rilpivirine. The study showed continued viral suppression after 48 weeks with no major safety concerns.

SourceSt. Jude Children's Research Hospital·JournalThe Lancet·TypeExperimental study·DateJan 15, 2026

Canada’s reduced pledge to Global Fund will impact domestic health

A reduced pledge by Canada to the Global Fund could lead to decreased success in controlling tuberculosis and HIV/AIDS in the country. The authors of an editorial urge Canada's government to invest in improving social determinants of health and implement disease-specific suggestions to address these pressing global health issues.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeCommentary/editorial·DateDec 15, 2025

A testing paradox for sexually transmitted infections

A new modeling study suggests that regular testing for sexually transmitted infections (STIs) can successfully reduce their spread, even if individuals on PrEP engage in riskier behavior. The paradoxical findings highlight the importance of careful surveillance data interpretation when evaluating public health interventions.

SourceMax Planck Institute for Dynamics and Self-Organization·JournalProceedings of the National Academy of Sciences·TypeComputational simulation/modeling·DateDec 15, 2025